EMERGENT BIOSOLUTIONS INC (EBS)       13.47  +0.35 (+2.67%)

Company Profile

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for PHTs through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The company offers TEMBEXA (brincidofovir) an antiviral for the treatment of smallpox in all age groups, including adults, and for patients who have difficulty swallowing.

Company Info

EMERGENT BIOSOLUTIONS INC

400 Professional Dr, Suite 400

Gaithersburg MARYLAND 20879

P: 12406313200.0

CEO: Robert G. Kramer

Employees: 2416

Website: https://emergentbiosolutions.com/